Efficacy and safety of rituximab treatment in Indian pemphigus patients

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages

  Kanwar, A J ^a   Tsuruta, D ^b   Vinay, K ^a   Koga, H ^b   Ishii, N ^b   Dainichi, T ^b   Hashimoto, T ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; DEXAMETHASONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BODY SURFACE; CHILD; CHILL; CLINICAL ARTICLE; DISEASE CONTROL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INFUSION RELATED REACTION; LOW DRUG DOSE; MALE; PEMPHIGUS; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SEPSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PEMPHIGUS; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84872858374     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04391.x     Document Type: Article

References (29)

1. Kaur S, Kanwar AJ,. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29: 371-374.
2. Kanwar AJ, De D,. Pemphigus in India. Indian J Dermatol Venereol Leprol 2011; 77: 439-449.
3. Bystryn JC, Steinman NM,. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-212.
4. Schmidt E, Brocker EB, Goebeler M,. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008; 34: 56-64.
5. Schmidt E, Goebeler M, Zillikens D,. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-691.
6. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66: 142-144.
7. Salopek TG, Logsetty S, Tredget EE,. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47: 785-788.
8. Goebeler M, Herzog S, Brocker EB, Zillikens D,. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149: 899-901.
9. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
10. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
11. D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA,. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr Metab Immune Disord Drug Targets 2008; 8: 62-68.
12. Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552-558.
13. Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone, and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2011; Forthcoming Sep12. doi: 10.1111/j.1365-2133.2011. 10585.x.
14. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR,. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
15. Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033-1038.
16. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-552.
17. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
18. Ikeda S, Imamura S, Hashimoto I, et al. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295 (Suppl. 1): S12-S16.
19. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-2017.
20. Kanwar AJ, Ajith AC, Narang T,. Pemphigus in North India. J Cutan Med Surg 2006; 10: 21-25.
21. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6: 366-373.
22. Kanwar AJ, Kaur S, Thami GP,. Long-term efficacy of dexamethasone- cyclophosphamide pulse therapy in pemphigus. Dermatology 2002; 204: 228-231.
23. Goh MS, McCormack C, Dinh HV, et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007; 156: 990-996.
24. Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145: 529-535.
25. Schiavo AL, Puca RV, Ruocco V, Ruocco E,. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies. Clin Dermatol 2010; 28: 337-343.
26. Kanwar AJ, Dhar S,. Factors responsible for death in patients with pemphigus. J Dermatol 1994; 21: 655-659.
27. Kong HH, Prose NS, Ware RE, Hall RP III,. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005; 22: 461-464.
28. Kanwar AJ, Dhar S, Kaur S,. Further experience with pemphigus in children. Pediatr Dermatol 1994; 11: 107-111.
29. Kanwar AJ, Dhar S,. Pemphigus in pregnancy: fetal risk. Int J Gynaecol Obstet 1993; 42: 176-177.